Sinner at Even Money: What a Knee Injury and a Depleted Draw Mean for the 2026 US Open Market

The world No. 1, winner of 87% of his matches this year and fresh off a Wimbledon title, is trading at exactly even odds to win the US Open. The reason is a right knee that currently needs shockwave therapy in Turin rather than hard-court practice in New York.

TL;DR

Jannik Sinner is the statistical favorite for the 2026 US Open but is priced at 50¢ YES due to an unresolved right knee injury.
He withdrew from Cincinnati on August 11 and is undergoing treatment in Italy; his entry to the US Open remains unconfirmed as of press time.
Chief rival Carlos Alcaraz has not played since April and is himself a question mark for the tournament, leaving the draw unusually open.
If Sinner withdraws, the market resolves NO; if he plays healthy, the 50¢ price looks like a significant discount on the actual win probability.

What the Market Says

The Polymarket contract "Will Jannik Sinner win the 2026 Men's US Open?" was priced at 50¢ YES and 50¢ NO as of 2026-08-16 10:26 UTC, on 24-hour volume of $5,833. That is a perfectly split market — which is either a statement of genuine uncertainty or evidence that two very different theses are in a temporary standoff.

The other notable prices in the field, as observed at press time: Alexander Zverev at 13¢, Carlos Alcaraz at 12¢, and Novak Djokovic at 7¢. Sinner's 50¢ share is therefore larger than the rest of the named field combined. That is what it looks like when a market is trying to price one binary question — does Sinner play, and if so, does the tournament unfold normally — rather than a straightforward horse race.

The Case

Start with the fundamentals. Sinner is the defending US Open champion, having won the title in 2024. He won Wimbledon last month. His match-win rate across all tour levels this year is 87%. On any given surface in any given year, those numbers describe the clear favorite for a Grand Slam.

Now subtract the competition. Alcaraz, who beat Sinner in the 2025 US Open final and is the defending champion, has not set foot on a match court since April. Right wrist tenosynovitis pulled him from the French Open, Wimbledon, and Cincinnati. His presence in New York is uncertain. Djokovic, at 7¢, recently lost to a player ranked 50th at Cincinnati and has acknowledged an undisclosed multi-year health condition. Zverev, the most credible threat at 13¢, reached the French Open final this year — respectable, but he is being priced at roughly one-quarter of Sinner's implied probability.

In other words, the draw is hollowed out in a way that rarely happens at a major. The 50¢ price is not really a commentary on Sinner's ability to win the tournament if healthy. It is a commentary on whether he gets on the plane.

On August 11, Sinner withdrew from the Cincinnati Masters citing right knee pain. Four days later, La Gazzetta dello Sport, as reported by Tennishead, confirmed he had returned to J Medical in Turin for shockwave therapy and supervised physical exercises under physiotherapist Gianluca Melegati. The team's public position, quoted by Tennishead: "until he sets foot on Arthur Ashe Stadium we shouldn't take anything for granted." His camp expects to make a travel decision sometime next week, which leaves approximately 14 days before the main draw begins August 30.

The arithmetic here is straightforward. If a bettor assigns even a 65% probability that Sinner plays and is sufficiently healthy to perform at his normal level, and then applies his historical win rate in Slams of that caliber, the expected value on a 50¢ YES position looks positive. The market appears to be pricing participation risk heavily — which makes sense, but the therapy reports are described as positive, and Sinner's team has not ruled out New York.

Risks

Shockwave therapy is a legitimate treatment for tendon and soft-tissue knee injuries, but it does not operate on a guaranteed timeline. Fourteen days is a narrow window. A hard-court Grand Slam is five rounds of best-of-five sets on one of the more physically demanding surfaces in tennis. Playing at 80% health at the US Open is not the same as playing at 80% health at an ATP 500.

Even if Sinner arrives in New York fully fit, there are structural risks. Zverev has beaten him in their two most recent head-to-head meetings. The upper half or lower half of the draw could stack unfavorably. An unpredictable opponent — the kind who specializes in upsets on fast hard courts — can end any player's tournament before the second week.

The starkest risk is binary: if Sinner officially withdraws from the US Open, the contract resolves NO at 0¢. A trader holding YES at 50¢ loses the full position. That is not a tail risk; it is a named, plausible scenario that is presumably responsible for a substantial portion of the NO side's current pricing. Watch for Sinner's team announcement next week. If he confirms his entry, expect the YES price to move meaningfully upward. If he scratches, the contract closes immediately.

There is also the question of what happens to Alcaraz. The 12¢ price on Alcaraz implies the market gives him roughly a one-in-eight chance of winning — respectable for a defending champion with his record, but clearly reflecting the four-month layoff. If Alcaraz confirms his withdrawal before the draw, some of that probability presumably flows to Sinner and Zverev, nudging Sinner's YES price higher even before a ball is struck.

The honest summary: 50¢ on Sinner is a market that has correctly identified the uncertainty and is waiting for more information. The directional bet is on when that information arrives, not on whether Sinner is the better player.

Prices captured at press time and are not live. Not financial advice. Independent publication - not affiliated with Polymarket, Banana Gun, or any venue.